Danib 100 mg (Tablet)
Unit Price: ৳ 435.00 (3 x 10: ৳ 13,050.00)
Strip Price: ৳ 4,350.00
Medicine Details
Category | Details |
---|---|
Generic | Dasatinib |
Company | Healthcare pharmaceuticals ltd |
Indications
- Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
- Treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib
- Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
- Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
- Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy
Pharmacology
- Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases at nanomolar concentrations
- Predicted binding to multiple conformations of the ABL kinase
- Active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
- Metabolism primarily by CYP3A4, FMO-3, and UGT enzymes
Dosage & Administration
- Recommended starting dosage for chronic phase CML in adults: 100 mg orally once daily
- Recommended starting dosage for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg orally once daily
- Dosage for pediatric patients based on body weight
- Tablets should not be crushed, cut, or chewed; they should be swallowed whole
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Potential for decreased concentrations with strong CYP3A4 inducers
- Potential for decreased concentrations with gastric acid reducing agents
Contraindications
- Known hypersensitivity to Dasatinib or any component of the formulation
Side Effects
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
Pregnancy & Lactation
- Potential fetal harm
- Recommendation to avoid pregnancy and use effective contraceptive methods during treatment
- Not recommended during breastfeeding
Precautions & Warnings
- Severe myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
Overdose Effects
- Limited clinical study experience with overdose
- Severe myelosuppression and bleeding observed in reported cases
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C in a dry place
- Protect from light
- Keep out of the reach of children